TA
GALT icon

Tiedemann Advisors’s Galectin Therapeutics GALT Stock Holding History

Tiedemann Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,000
Closed -$22K – 129
2016
Q2 		$22K Buy
+15,000
New +$22K 0.02% 56

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Tiedemann Advisors's GALT Position: Q3 2016 in Review

Tiedemann Advisors sold out of Galectin Therapeutics (GALT) in Q3 2016, closing a stake of 15,000 shares — an estimated $22K sold.

Tiedemann Advisors first reported a position in GALT in Q2 2016 and held it in 1 quarter. The position peaked at $22K in Q2 2016. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

  • Tiedemann Advisors reported no remaining Galectin Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Tiedemann Advisors sold 15,000 Galectin Therapeutics shares in Q3 2016, an estimated $22K.
  • Tiedemann Advisors first reported a position in Galectin Therapeutics in Q2 2016 and held it in 1 quarter.
  • Tiedemann Advisors's Galectin Therapeutics position peaked at $22K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on Tiedemann Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.